Combining Three Drugs in the Treatment of Multiple Myeloma Patients Shows Solid Clinical Activity
source: pixabay.com

Combining Three Drugs in the Treatment of Multiple Myeloma Patients Shows Solid Clinical Activity

  According to data from the STOMP trial involving thirty-four patients, a triple regimen has been proven to induce durable responses in pretreated patients with relapsed/refractory multiple myeloma. A recent…

Continue Reading Combining Three Drugs in the Treatment of Multiple Myeloma Patients Shows Solid Clinical Activity
Patient Treated for Multiple Myeloma Develops Myasthenia Gravis: Case Study
source: pixabay.com

Patient Treated for Multiple Myeloma Develops Myasthenia Gravis: Case Study

According to a story from Myasthenia Gravis News, a recent case report describes a unique case of a 60 year old male multiple myeloma patient. After receiving treatment for the…

Continue Reading Patient Treated for Multiple Myeloma Develops Myasthenia Gravis: Case Study
Genomic Markers Show the Risk of Progression for Smoldering Multiple Myeloma
mohamed_hassan / Pixabay

Genomic Markers Show the Risk of Progression for Smoldering Multiple Myeloma

According to the ASCO Post, researchers have discovered genomic characteristics of smoldering multiple myeloma that can tell one's risk of progression to multiple myeloma. Dr. Mark Bustoros and his team…

Continue Reading Genomic Markers Show the Risk of Progression for Smoldering Multiple Myeloma

CASI Pharmaceuticals Files CTA (IND) for Novel Multiple Myeloma Treatment

  According to a recent press release, biopharmaceutical company CASI Pharmaceuticals filed a Clinical Trial Application (CTA) (IND) in the United Kingdom. CASI Pharmaceuticals is hoping to test the safety…

Continue Reading CASI Pharmaceuticals Files CTA (IND) for Novel Multiple Myeloma Treatment
Coronavirus/COVID-19: What Cancer Patients, Caregivers, and Survivors Need to Know
source: pixabay.com

Coronavirus/COVID-19: What Cancer Patients, Caregivers, and Survivors Need to Know

According to a story from LocalHealthGuide, COVID-19 has continued to spread through the US and the lackluster government response suggests that it isn't going to be contained any time soon.…

Continue Reading Coronavirus/COVID-19: What Cancer Patients, Caregivers, and Survivors Need to Know
Trial Testing Combination Treatment for Untreated Multiple Myeloma Ends in Disappointment
source: pixabay.com

Trial Testing Combination Treatment for Untreated Multiple Myeloma Ends in Disappointment

According to a story from businesswire.com, the Bristol Myers Squibb Company recently released the topline results from its phase 3 clinical trial. This study was testing a combination treatment consisting…

Continue Reading Trial Testing Combination Treatment for Untreated Multiple Myeloma Ends in Disappointment
Four Drug Combination to Treat Multiple Myeloma Performs Well in Trial
source: pixabay.com

Four Drug Combination to Treat Multiple Myeloma Performs Well in Trial

  According to a report in Myeloma Research News, the European Commission has recently granted authorization to market bortezomib, dexamethasone and thalidomide (collectively known as VTd) plus daratumumab to treat…

Continue Reading Four Drug Combination to Treat Multiple Myeloma Performs Well in Trial
ICYMI: An Observational Blood Cancer Study is Starting to Recruit Patients
source: pixabay.com

ICYMI: An Observational Blood Cancer Study is Starting to Recruit Patients

According to a story from Financial Buzz, the precision oncology company Notable has recently announced that it has opened enrollment for a new observational clinical trial that will focus on…

Continue Reading ICYMI: An Observational Blood Cancer Study is Starting to Recruit Patients

FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time

  The biopharmaceutical company Cellectar Biosciences recently announced that the FDA granted its lead phospholipid drug conjugate, CLR 131, Orphan Drug Designation(ODD) for treatment of lymphoplasmacytic lymphoma. ODD is granted by…

Continue Reading FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time
Study: Belantamab Mafodotin Shows Positive Results in People with Multiple Myeloma
https://pixabay.com/en/blood-blood-plasma-red-blood-cells-75301/

Study: Belantamab Mafodotin Shows Positive Results in People with Multiple Myeloma

Copyscape score: 4% Cancer is a disease that affects different people in different ways, and for some people, no existing treatments can effectively treat their cancer. GlaxoSmithKline has recently released…

Continue Reading Study: Belantamab Mafodotin Shows Positive Results in People with Multiple Myeloma
First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial
source: pixabay.com

First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial

According to a story from Myeloma Research News, the first patient has been dosed with an experimental allogeneic (donor derived) CAR-T cell therapy called UCARTCS1 as part of a phase…

Continue Reading First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial
Study Finds Under-Use of Supportive Care in Older Multiple Myeloma Patients
pasja1000 / Pixabay

Study Finds Under-Use of Supportive Care in Older Multiple Myeloma Patients

According to a story from Healio, a recent study has determined that older patients with multiple myeloma, a rare cancer that affects plasma cells, routinely under-utilize supportive care resources as…

Continue Reading Study Finds Under-Use of Supportive Care in Older Multiple Myeloma Patients
Close Menu